Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.

Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.

He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.

Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).